The closing price of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) was $3.41 for the day, up 3.33% from the previous closing price of $3.30. In other words, the price has increased by $+0.1100 from its previous closing price. On the day, 932612 shares were traded.
Ratios:
Our analysis of MREO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.11 and its Current Ratio is at 3.11. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.08.
On August 12, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $4.
On May 05, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $10.BTIG Research initiated its Buy rating on May 05, 2021, with a $10 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MREO now has a Market Capitalization of 478.28M and an Enterprise Value of 426.81M. For the stock, the TTM Price-to-Sale (P/S) ratio is 54.33 while its Price-to-Book (P/B) ratio in mrq is 5.96. Its current Enterprise Value per Revenue stands at 42.68 whereas that against EBITDA is -16.38.
Stock Price History:
Over the past 52 weeks, MREO has reached a high of $4.36, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 3.5614, while the 200-Day Moving Average is calculated to be 2.1911.
Shares Statistics:
MREO traded an average of 1.78M shares per day over the past three months and 1.15M shares per day over the past ten days. A total of 140.06M shares are outstanding, with a floating share count of 140.06M. Insiders hold about 0.00% of the company’s shares, while institutions hold 61.40% stake in the company. Shares short for MREO as of Mar 15, 2024 were 2.19M with a Short Ratio of 1.23, compared to 2.78M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.56% and a Short% of Float of 2.17%.
Earnings Estimates
The firm’s stock currently is rated by 0 analysts. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
